Elahere
mirvetuximab soravtansine · FRαRationale not stated; FIH Study 0401 escalated from 0.15 mg/kg (TBW) to 7.0 mg/kg
The public FDA and EMA reviews of Trodelvy don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.
ADCs with cytotoxic payloads follow the S9 rules (1/10 STD10 or 1/6 HNSTD of the ADC, scaled by body surface area). For immune agonists, a MABEL-based start dose should be considered instead.
NOAEL / key findings: Acute study HNSTD 60 mg/kg (no NOAEL); 13-week NOAEL/HNSTD 50 mg/kg; bone marrow, lymphoid, GI, liver, skin, female reproductive organs (EMA assessment report, p. 30)